SLFN5 and breast cancer: As a transcriptional repressor, SLFN5 prevents epithelial-mesenchymal transition (EMT) in breast cancer and targets the ZEB1 promoter to suppress ZEB1 transcription and downstream PTEN/AKT/cyclin D1 signaling cascade, ultimately inducing cancer cell death (28, 29).